Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres
Authors:
- Gautham NairGNGautham Nair
- Morgan BlackMBMorgan Black
- Kathie BaerKBKathie Baer
- Stephen WelchSWStephen Welch
- David T. LaidleyDLDavid T. Laidley
- Rachel GoodwinRGRachel Goodwin
- Macyn LeungMLMacyn Leung
- William J. PhillipsWPWilliam J. Phillips
- Michael VickersMichael Vickers
- Tim AsmisTim Asmis
- Horia MargineanHMHoria Marginean
- Elena TsvetkovaETElena Tsvetkova
Open Access
- 3 February 2025
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 32 (2) , 86
Abstract
Pancreatic neuroendocrine tumors (pNETs) are rare but increasingly prevalent malignancies with varied prognoses and a diverse range of treatment options, including surgery, somatostatin analogues (SSAs), chemotherapy, targeted therapy, and peptide receptor radionuclide therapy (PRRT). This retrospective cohort study analyzed treatment patterns among 189 pNET patients treated between January 2010 and June 2021 at two Canadian cancer centres: the Verspeeten Family Cancer Centre (VFCC), which offers PRRT, and the Ottawa Hospital Cancer Centre (TOHCC), which does not at the time of the study. Data on demographics, tumor characteristics, and treatment modalities were collected, and statistical analyses were conducted using chi-square, Fisher’s exact test, and the Kruskal–Wallis test. Among eligible patients, 53% presented with stage IV disease. Surgical resection was the most common treatment, followed by SSAs, chemotherapy, PRRT, and targeted therapy. Stage IV patients at VFCC were significantly more likely to receive PRRT (60%) compared to TOHCC (6%) and underwent more PRRT cycles, with a higher prevalence of well-differentiated tumors observed at VFCC. With these differences it was clear that the non-PRRT centre was unable to provide patients with the same level of PRRT access during the study period compared to patients seen at the PRRT site. The findings underscore the critical role of PRRT availability in influencing treatment patterns and highlight the need for equitable access to specialized therapies across Canada to optimize outcomes for pNET patients.Keywords
Funding Information
- Ipsen Biopharmaceuticals (12633)
This publication has 19 references indexed in Scilit:
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs)Surgery, 2019
- Long-term Outcomes of Gastroenteropancreatic Neuroendocrine TumorsPancreas, 2018
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology, 2017
- Radionuclide Therapy for Neuroendocrine TumorsCurrent Oncology Reports, 2017
- Rural‐urban disparities in incidence and outcomes of neuroendocrine tumors: A population‐based analysis of 6271 casesCancer, 2015
- Exploring the rising incidence of neuroendocrine tumors: A population‐based analysis of epidemiology, metastatic presentation, and outcomesCancer, 2014
- Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experienceCancer Chemotherapy and Pharmacology, 2013
- Surgical resection of hepatic metastases from neuroendocrine neoplasms: A systematic reviewSurgical Oncology, 2012
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009